Clinical Scorecard: Indicators of Axonal Damage in Blood and Tissue Induced by Acute and Chronic Demyelination
At a Glance
Category
Detail
Condition
Demyelinating diseases including multiple sclerosis
Key Mechanisms
Neuroaxonal injury driven by demyelination; neurofilament light chain (NfL) release as a biomarker of axonal damage
Target Population
People with multiple sclerosis and animal models of demyelination
Care Setting
Neurology clinical and research settings focusing on neurodegenerative and demyelinating disorders
Key Highlights
Blood NfL levels correlate robustly with tissue neuroaxonal injury and severity of inflammatory demyelination in experimental autoimmune encephalomyelitis (EAE).
Inducible genetic demyelination models show serum NfL peaks during demyelination and decreases following remyelination.
In multiple sclerosis patients, NfL levels associate with myelin breakdown proteins, supporting NfL as a translational biomarker for neuroaxonal pathology.
Guideline-Based Recommendations
Diagnosis
Use blood NfL measurement as a biomarker to monitor neuroaxonal injury longitudinally in demyelinating diseases.
Combine NfL assays with proteomic approaches to assess myelin integrity and neurodegeneration.
Management
Consider treatments that promote remyelination to reduce NfL levels and potentially mitigate neuroaxonal injury.
Monitor NfL levels to evaluate therapeutic efficacy, including remyelinating agents like clemastine.
Monitoring & Follow-up
Regularly measure serum NfL to track disease activity and neuroaxonal damage progression in multiple sclerosis.
Use NfL dynamics to assess response to disease-modifying therapies and remyelination interventions.
Risks
Elevated NfL indicates ongoing neuroaxonal injury and risk of irreversible disability.
Interpret NfL changes considering that structural axonal damage is not the sole cause of elevation; myelin integrity alterations also influence levels.
Patient & Prescribing Data
People with multiple sclerosis undergoing disease-modifying or remyelinating treatments
NfL levels decrease following effective remyelination therapy, suggesting neuroprotection and potential reversibility of axonal pathology.
Clinical Best Practices
Incorporate blood NfL assays as part of routine monitoring in demyelinating conditions to detect neuroaxonal injury early.
Use animal models of demyelination to understand NfL biology and validate biomarkers before clinical application.
Interpret NfL results in the context of both inflammatory activity and myelin integrity changes for comprehensive patient assessment.
by Ahmed Abdelhak, Christian Cordano, Greg J Duncan, Katie Emberley, Sonia Nocera, Wendy Xin, Kirtana Ananth, Nour Jabassini, Kiarra Ning, Henriette Reinsberg, Frederike Cosima Oertel, Alexandra Beaudry-Richard, Jens Kuhle, Axel Petzold, Praveen J Patel, Ana P Ribeiro Reis, Paul J Foster, UKBB Eye and Vision Consortium, Trent Watkins, Jonah R Chan, Ben Emery, Ari J Green
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.
